Cargando…

TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs

Recently, two tropomycin receptor kinase (Trk) inhibitors, larotrectinib and entrectinib, have been approved for Trk fusion-positive cancer patients. Clinical trials for larotrectinib and entrectinib were performed with patients selected based on the presence of Trk fusion, regardless of cancer type...

Descripción completa

Detalles Bibliográficos
Autor principal:	Han, Sun-Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308490/ https://www.ncbi.nlm.nih.gov/pubmed/34209967 http://dx.doi.org/10.3390/ph14070632

Ejemplares similares

Drug Development in Tissue-Agnostic Indications
por: du Rusquec, Pauline, et al.
Publicado: (2021)

TRK inhibitors in TRK fusion-positive cancers
por: Drilon, A
Publicado: (2019)

Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?
por: Weis, Luiza N., et al.
Publicado: (2021)

Tumour-agnostic drugs in paediatric cancers
por: Chisholm, Julia C., et al.
Publicado: (2020)

Economic Evaluation of a Tumour-Agnostic Therapy: Dutch Economic Value of Larotrectinib in TRK Fusion-Positive Cancers
por: Michels, Renée E., et al.
Publicado: (2022)

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy
por: Gouda, M.A., et al.
Publicado: (2023)

Developing Drugs for Tissue‐Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine
por: Seligson, Nathan D., et al.
Publicado: (2020)

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
por: Adashek, Jacob J., et al.
Publicado: (2022)

Tissue-agnostic cancer drugs in the fight against molecular subsets of metastases of unknown origin
por: Roncati, Luca, et al.
Publicado: (2019)

The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer
por: Iannantuono, Giovanni Maria, et al.
Publicado: (2022)

Reply to ‘Comment on “Tumour-agnostic drugs in paediatric cancers”’
por: Chisholm, Julia C., et al.
Publicado: (2020)

Secretory carcinoma of major and minor salivary glands with ETV6-NTRK3 gene fusion: overcoming misdiagnosis in the era of tumour-agnostic therapy with TRK inhibitors
por: Durzyńska, Monika, et al.
Publicado: (2023)

Histology-Agnostic Drugs: A Paradigm Shift—A Narrative Review
por: Mansinho, André, et al.
Publicado: (2022)

The Bacillus Agnostic
Publicado: (1911)

Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group
por: Vranic, Semir, et al.
Publicado: (2022)

Characterization of KRC-108 as a TrkA Kinase Inhibitor with Anti-Tumor Effects
por: Lee, Hyo Jeong, et al.
Publicado: (2022)

Tumour-Agnostic Therapy for Pancreatic Cancer and Biliary Tract Cancer
por: Kato, Shunsuke
Publicado: (2021)

TRK inhibitors block NFKB and induce NRF2 in TRK fusion-positive colon cancer
por: Sohn, Sung-Hwa, et al.
Publicado: (2021)

Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics
por: Tateo, Valentina, et al.
Publicado: (2023)

Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers
por: Chen, Yu, et al.
Publicado: (2018)

Agnostic Tendency in Doctors
Publicado: (1885)

Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers
por: Cabel, Luc, et al.
Publicado: (2018)

Application of mTORC1 Inhibitors for Tissue-Agnostic Management of Standard-Therapy-Refractory Solid Tumors
por: Taghizadeh, Hossein, et al.
Publicado: (2022)

Review of the Agnostic-Type Treatment Approach: Treating Cancer by Mutations, Not by Location
por: Rosas, Daniel, et al.
Publicado: (2020)

Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma
por: Pacenta, Holly L, et al.
Publicado: (2018)

Outcome selection for tissue-agnostic drug trials for immune-mediated inflammatory diseases: a systematic review of core outcome sets and regulatory guidance
por: Aiyegbusi, Olalekan Lee, et al.
Publicado: (2022)

ALK fusions in the pan-cancer setting: another tumor-agnostic target?
por: Shreenivas, Aditya, et al.
Publicado: (2023)

TrkA Co-Receptors: The Janus Face of TrkA?
por: Trouvilliez, Sarah, et al.
Publicado: (2023)

Comment on: “Tumour-agnostic drugs in paediatric cancers”, Chisholm et al., BJC 2020
por: Oliver, Thomas Richard William, et al.
Publicado: (2020)

Precision medicine becomes reality—tumor type-agnostic therapy
por: Yan, Li, et al.
Publicado: (2018)

Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers
por: Jiang, Tingting, et al.
Publicado: (2021)

Pharmacogenetics of SGLT2 Inhibitors: Validation of a sex-agnostic pharmacodynamic biomarker
por: Taylor, Simeon I., et al.
Publicado: (2023)

The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair
por: Pacheco-Barcia, Vilma, et al.
Publicado: (2022)

Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia
por: Arai, Hironori, et al.
Publicado: (2022)

Inhibiting TRK Proteins in Clinical Cancer Therapy
por: Lange, Allison M., et al.
Publicado: (2018)

RET-Altered Cancers—A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy Activity
por: Desilets, Antoine, et al.
Publicado: (2023)

Resolution-agnostic tissue segmentation in whole-slide histopathology images with convolutional neural networks
por: Bándi, Péter, et al.
Publicado: (2019)

A zero-agnostic model for copy number evolution in cancer
por: Schmidt, Henri, et al.
Publicado: (2023)

A zero-agnostic model for copy number evolution in cancer
por: Schmidt, Henri, et al.
Publicado: (2023)

A pipeline for malignancy and therapy agnostic assessment of cancer drug response using cell mass measurements
por: Kimmerling, Robert J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_stg498i96orpdijjp334d6e42k